LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

That is why the market saw AbbVie make a number of acquisitions to expand its pipeline and offset that loss. In 2024, the ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

Cerevel Therapeutics (now part of AbbVie), Kailera Therapeutics, Stada, Tenacia Biotechnology, and Timberlyne Therapeutics. The firm is also a leading investor and partner to businesses across ...

In 2024, the company bought neuroscience-drug developer Cerevel Therapeutics, cancer-drug developer ImmunoGen, and Alzheimer's therapy developer Aliada, deals valued at a total of more than $20 ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

The company was recently forced to take a non-cash $3.5 billion loss on the $8.7 billion acquisition of Cerevel Therapeutics after its key schizophrenia therapy, a drug called emraclidine ...